PTC THERAPEUTICS, INC.

PTC Therapeutics, Inc. announced that its Board of Directors has authorized a share repurchase program allowing for the repurchase of up to $500 million of the Company's common stock. This move reflects the Board's confidence in the company's financial strength and future growth prospects. Repurchases can be executed through various methods at management's discretion, including open-market transactions and accelerated share repurchases, while ensuring the company maintains financial flexibility for existing programs and potential business development.

PTC Therapeutics, Inc. announced it was selected as the winning bidder to acquire ST-920, a BLA-stage one-time administered AAV gene therapy for Fabry disease, from Sangamo Therapeutics. The acquisition involves a $111 million upfront payment and up to $100 million in contingent milestone payments based on regulatory approvals. The company expects to complete a rolling BLA submission to the FDA for accelerated approval in Q4 2026, with a potential commercial launch in 2027, leveraging its existing rare disease infrastructure.

PTC Therapeutics reported a net income of $83.5 million for the second quarter of 2026, a significant improvement from a net loss of $64.8 million in the same period last year. Total revenues surged by 101.5% to $360.5 million, driven by strong net product revenue and a $50.0 million milestone payment from Novartis for the initiation of the votoplam Phase 3 clinical trial. The company also announced positive 24-month interim analysis results for votoplam in Huntington's disease and plans for new studies for vatiquinone and other pipeline candidates.

PTC Therapeutics announced strong second quarter 2026 financial results, with total revenue reaching $361 million and product revenue at $239 million. The company raised its full-year 2026 total revenue guidance to $1.18 billion to $1.28 billion and product revenue guidance to $850 million to $950 million. Additionally, Hege Sollie-Zetlmayer, former Chief Human Resources Officer, was appointed to the Board of Directors, effective immediately.

PTC Therapeutics, Inc. announced the completion of its previously disclosed private offering of $550 million aggregate principal amount of 0.0% Convertible Senior Notes due 2031. The offering included the full exercise of the initial purchasers' option for an additional $50 million in notes. These unsecured senior obligations will not bear regular interest and mature on June 15, 2031, with an initial conversion price of approximately $107.48 per share.

PTC Therapeutics, Inc. announced the pricing of a $500.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2031. The company also granted initial purchasers an option to buy an additional $50.0 million in notes. Approximately $328.8 million of the net proceeds will be used to repurchase $222.0 million of its outstanding 1.5% Convertible Senior Notes due 2026, with the remaining proceeds for general corporate purposes and further repurchases of the 2026 notes.

PTC Therapeutics, Inc. announced that Alethia Young resigned from its Board of Directors, effective June 8, 2026. Ms. Young cited the need to focus on other work commitments as the reason for her departure, clarifying there were no disagreements with the company. She will continue to serve as an advisor to PTC Therapeutics under a consulting agreement, receiving a monthly fee of $4,166.67 for a term extending through June 8, 2027.

PTC Therapeutics reported a net loss of $2.8 million for Q1 2026, a significant decline from a net income of $866.6 million in Q1 2025, primarily due to the absence of a large collaboration payment. Total revenues fell by 76.8% to $272.6 million. Despite the financial downturn, the company announced positive 24-month interim results for votoplam in Huntington's disease, showing a 52% slowing of disease progression, and Novartis commenced a global Phase 3 study for the drug.

PTC Therapeutics announced positive topline results from the 24-month interim analysis of the PIVOT-HD long-term extension study for votoplam in Huntington's disease. The study demonstrated a favorable dose-dependent slowing of disease progression in Stage 2 participants, with a 52% slowing at the 10 mg dose and 28% at the 5 mg dose compared to a natural history cohort. The safety profile remained favorable, and Novartis has initiated the global Phase 3 INVEST-HD study for votoplam, which will enroll approximately 770 early-stage HD patients.